
- Profit up but care down at many PE-backed nursing homes, says the New York Times in a Sunday feature.
- Pfizer gets maraviroc approval in the EU--here's the early morning release--and Novartis gets an EU OK for its transdermal Exelon mild-to-moderately-severe Alzheimer's disease patch. Both approvals were expected.
- The WSJ is the latest paper to take a gander at GSK's slightly unusual CEO succession contest, while the FT wonders who will replace Jon Symonds as CFO at AZ (hat tip, Pharmagossip).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.